StockData
CNS Pharmaceuticals, Inc. logo

CNS Pharmaceuticals, Inc. (CNSP) stock

CNSPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$4.15+0.67 (+19.25%)

Close on Nov 17, 2026Market cap $6.07MP/E –Yield –

CNS Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

CNS Pharmaceuticals's cash was $19.99M at Jun 30, 2026. For fiscal 2025 it was $7.20M, up 11.5% from the year before. The highest annual figure on record is $14.04M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.20M+11.5%
FY2024Dec 31, 2024$6.46M+1077.5%
FY2023Dec 31, 2023$548.72K-94.5%
FY2022Dec 31, 2022$10.06M+100.9%
FY2021Dec 31, 2021$5.00M-64.4%
FY2020Dec 31, 2020$14.04M+93.9%
FY2019Dec 31, 2019$7.24M+1204.4%
FY2018Dec 31, 2018$555.13K+402.2%
FY2017Dec 31, 2017$110.54K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$19.99M+64.8%
Q1 FY2026Mar 31, 2026$2.95M-77.4%
Q4 FY2025Dec 31, 2025$7.20M+11.5%
Q3 FY2025Sep 30, 2025$9.86M+41.5%
Q2 FY2025Jun 30, 2025$12.13M+713.2%
Q1 FY2025Mar 31, 2025$13.05M+1500.5%
Q4 FY2024Dec 31, 2024$6.46M+1077.5%
Q3 FY2024Sep 30, 2024$6.97M+666.7%
Q2 FY2024Jun 30, 2024$1.49M-65.1%
Q1 FY2024Mar 31, 2024$815.23K-84.0%
Q4 FY2023Dec 31, 2023$548.72K-94.5%
Q3 FY2023Sep 30, 2023$909.55K-87.1%
Q2 FY2023Jun 30, 2023$4.28M-52.2%
Q1 FY2023Mar 31, 2023$5.11M-58.9%
Q4 FY2022Dec 31, 2022$10.06M+100.9%
Q3 FY2022Sep 30, 2022$7.03M-15.6%
Q2 FY2022Jun 30, 2022$8.96M+30.1%
Q1 FY2022Mar 31, 2022$12.44M+12.3%
Q4 FY2021Dec 31, 2021$5.00M-64.4%
Q3 FY2021Sep 30, 2021$8.33M+537.0%
Q2 FY2021Jun 30, 2021$6.89M+162.2%
Q1 FY2021Mar 31, 2021$11.08M+105.9%
Q4 FY2020Dec 31, 2020$14.04M+93.9%
Q3 FY2020Sep 30, 2020$1.31M+107.4%
Q2 FY2020Jun 30, 2020$2.63M+187.9%
Q1 FY2020Mar 31, 2020$5.38M+3370.4%
Q4 FY2019Dec 31, 2019$7.24M+1204.4%
Q3 FY2019Sep 30, 2019$630.11K-11.1%
Q2 FY2019Jun 30, 2019$911.93K+725.0%
Q1 FY2019Mar 31, 2019$155.02K–
Q4 FY2018Dec 31, 2018$555.13K–
Q3 FY2018Sep 30, 2018$708.63K–
Q4 FY2017Dec 31, 2017$110.54K–

More CNS Pharmaceuticals figures

See a number that looks wrong?